Published in Adv Pharmacol on January 01, 2014
Nicotinic receptor modulation to treat alcohol and drug dependence. Front Neurosci (2015) 0.85
Synthesis and Pharmacological Evaluation of DHβE Analogues as Neuronal Nicotinic Acetylcholine Receptor Antagonists. ACS Med Chem Lett (2014) 0.85
Efficient expression of functional (α6β2)2β3 AChRs in Xenopus oocytes from free subunits using slightly modified α6 subunits. PLoS One (2014) 0.80
r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochem Res (2015) 0.76
Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies. J Clin Pharm Ther (2014) 0.76
Unorthodox Acetylcholine Binding Sites Formed by α5 and β3 Accessory Subunits in α4β2* Nicotinic Acetylcholine Receptors. J Biol Chem (2016) 0.75
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.75
Cytisine inhibits the protective activity of various classical and novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice. Psychopharmacology (Berl) (2016) 0.75
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem (2005) 6.13
Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol (2007) 5.48
Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol (2004) 4.58
Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci (2006) 4.04
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol (2006) 3.84
Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol (1995) 3.37
A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol (1992) 3.20
Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol (1989) 3.08
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) (1992) 2.97
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol (2009) 2.90
Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ (2013) 2.86
A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors. J Biol Chem (1996) 2.76
Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax (2013) 2.74
In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron (2008) 2.69
Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci (2008) 2.52
Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology (2008) 2.49
Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology (Berl) (2005) 2.41
Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl) (2005) 2.27
Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther (2000) 2.26
Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology (2007) 2.23
Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J Neurosci (1998) 2.18
The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol (2007) 2.03
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health (2006) 1.91
Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. Mol Pharmacol (2007) 1.86
The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. J Neurosci (2003) 1.73
Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther (1999) 1.67
Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci (1996) 1.65
Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology (2007) 1.63
Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol (2006) 1.62
Purification and characterization of a nicotinic acetylcholine receptor from rat brain. Proc Natl Acad Sci U S A (1987) 1.62
The increasing recalcitrance of smokers in clinical trials II: Pharmacotherapy trials. Nicotine Tob Res (2003) 1.60
Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J Biol Chem (1991) 1.57
Subcellular trafficking, pentameric assembly, and subunit stoichiometry of neuronal nicotinic acetylcholine receptors containing fluorescently labeled alpha6 and beta3 subunits. Mol Pharmacol (2007) 1.52
Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors. Mol Pharmacol (2008) 1.48
The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. J Pharmacol Exp Ther (2009) 1.45
Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med (2006) 1.44
N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. J Pharmacol Exp Ther (2008) 1.44
Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. J Neurosci (1996) 1.42
Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors. J Neurosci (2010) 1.41
Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion. Mol Pharmacol (2005) 1.38
Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther (1994) 1.38
Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol (2003) 1.36
Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett (2004) 1.36
Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology (Berl) (2005) 1.35
Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. J Neurosci (1997) 1.35
Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nicotine. Neuropsychopharmacology (2009) 1.34
Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J Neurochem (1996) 1.33
Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol (2009) 1.31
Molecular mechanisms underlying behaviors related to nicotine addiction. Cold Spring Harb Perspect Med (2013) 1.28
Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers. Mol Pharmacol (2010) 1.28
A novel alpha-conotoxin, PeIA, cloned from Conus pergrandis, discriminates between rat alpha9alpha10 and alpha7 nicotinic cholinergic receptors. J Biol Chem (2005) 1.26
Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery. J Pharmacol Exp Ther (2001) 1.25
Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev (2013) 1.22
AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology (2012) 1.22
Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. J Neurochem (2001) 1.21
Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci (2004) 1.19
bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors. Bioorg Med Chem Lett (2002) 1.17
The alpha 5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron (1992) 1.17
Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology (Berl) (2005) 1.14
Bupropion increases striatal vesicular monoamine transport. Neuropharmacology (2005) 1.14
Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett (2004) 1.13
Nicotinic cholinergic receptors in the rat cerebellum: multiple heteromeric subtypes. J Neurosci (2005) 1.11
Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol (2009) 1.09
Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther (2010) 1.08
Reinforcing effects of nicotine and non-nicotine components of cigarette smoke. Psychopharmacology (Berl) (2010) 1.07
Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metab Dispos (2008) 1.07
Differential inhibition by alpha-conotoxin-MII of the nicotinic stimulation of [3H]dopamine release from rat striatal synaptosomes and slices. J Neurochem (1998) 1.06
Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. J Pharmacol Exp Ther (2007) 1.06
Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J (2009) 1.06
Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier. J Pharmacol Exp Ther (2007) 1.06
The road to discovery of neuronal nicotinic cholinergic receptor subtypes. Handb Exp Pharmacol (2009) 1.04
Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol Sci (2005) 1.04
Do small lapses predict relapse to smoking behavior under bupropion treatment? Nicotine Tob Res (2004) 1.03
A comparative study of the effects of the intravenous self-administration or subcutaneous minipump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes. Mol Pharmacol (2010) 1.03
Ultrastructural localization of the alpha4-subunit of the neuronal acetylcholine nicotinic receptor in the rat substantia nigra. J Neurosci (1999) 1.02
Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett (2007) 1.00
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebr Symp Motiv (2009) 1.00
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther (2003) 0.99
Nicotine self-administration. Nicotine Tob Res (1999) 0.98
Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs (2006) 0.98
The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.98
Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo. Br J Pharmacol (2007) 0.97
Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. Expert Opin Pharmacother (2009) 0.96
Disrupting nicotine reinforcement: from cigarette to brain. Ann N Y Acad Sci (2008) 0.95
Heteromeric nicotinic acetylcholine-dopamine autoreceptor complexes modulate striatal dopamine release. Neuropsychopharmacology (2006) 0.95
Immunohistochemical localization of the nicotinic acetylcholine receptor subunit alpha6 to dopaminergic neurons in the substantia nigra and ventral tegmental area. Neuroreport (1997) 0.93
Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation. Bioorg Med Chem Lett (2007) 0.93
QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release. Bioorg Med Chem (2006) 0.93
Pharmacological and null mutation approaches reveal nicotinic receptor diversity. Eur J Pharmacol (2000) 0.92
Nicotine gum as a substitute for cigarettes: a behavioral economic analysis. Behav Pharmacol (2000) 0.91
bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol (2011) 0.91
Preclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotype. Nicotine Tob Res (2012) 0.91
Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochem Pharmacol (2010) 0.89
Formation of oligomers containing the beta3 and beta4 subunits of the rat nicotinic receptor. J Neurosci (1997) 0.89
Development of a novel class of subtype-selective nicotinic receptor antagonist: pyridine-N-substituted nicotine analogs. Ann N Y Acad Sci (1999) 0.89
Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorg Med Chem Lett (2008) 0.89
Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers. Pharmacol Biochem Behav (2000) 0.88
Beta-subunits co-determine the sensitivity of rat neuronal nicotinic receptors to antagonists. Pflugers Arch (1995) 0.88